Get the Stockscreener App
16.27
2.11%
-0.35
After Hours:
16.50
0.23
+1.41%
Viridian Therapeutics Inc stock is traded at $16.27, with a volume of 839.42K.
It is down -2.11% in the last 24 hours and down -11.62% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
See More
Previous Close:
$16.62
Open:
$16.81
24h Volume:
839.42K
Relative Volume:
0.65
Market Cap:
$1.29B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.8282
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
-0.79%
1M Performance:
-11.62%
6M Performance:
+4.43%
1Y Performance:
-12.15%
1-Day Range:
$16.25
$16.97
1-Week Range:
$15.62
$16.97
52-Week Range:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
16.27 | 1.29B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Where are the Opportunities in (VRDN) - Stock Traders Daily
What Do Wall Street Analysts Think About Viridian Therapeutics Inc (NASDAQ: VRDN) Stock? - Stocks Register
Rice Hall James & Associates LLC Takes Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5%Should You Sell? - MarketBeat
Viridian Therapeutics Inc (NASDAQ: VRDN): Slumped -0.56% In 2025, Outlook Stable - Stocks Register
Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt? - Simply Wall St
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Here's Why - MarketBeat
(VRDN) Trading Advice - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% – Should You Sell? - Armenian Reporter
VRDN Stock Sees Decline of Approximately -7.82% in Last Five Days - Knox Daily
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian's Strategic Expansion: 527,750 Share Options Awarded as TED Programs Advance - StockTitan
Analyzing Ratios: Viridian Therapeutics Inc (VRDN)’s Financial Story Unveiled - The Dwinnex
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
This trade activity should not be overlooked: Viridian Therapeutics Inc (VRDN) - SETE News
Wells Fargo Downgrades Viridian Therapeutics Inc (VRDN) to an Equal weight from an Overweight - Knox Daily
SG Americas Securities LLC Purchases 14,644 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat
Moody Aldrich Partners LLC Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat
FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat
SG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Equities Analysts Offer Predictions for VRDN Q1 Earnings - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings? - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat
JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Sling Brings Potential Oral Competition To Amgen’s Tepezza In TED - News & Insights
Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace
Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com
(VRDN) Investment Analysis - Stock Traders Daily
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):